Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)

• Published in: The American journal of cardiology Vol. 114; no. 11; pp. 1682 - 1689
• Main Authors: Everett, Brendan M., Mora, Samia, Glynn, Robert J., MacFadyen, Jean, Ridker, Paul M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2014; Elsevier Limited
• Subjects: Aged; Apolipoproteins; Cardiovascular; Cholesterol; Cholesterol, LDL - blood; Diabetes; Diabetes Mellitus, Type 2 - epidemiology; Double-Blind Method; Female; Fluorobenzenes - therapeutic use; Hematuria - epidemiology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Insomnia; Kinases; Liver Diseases - epidemiology; Low density lipoprotein; Male; Metabolism; Middle Aged; Odds Ratio; Proportional Hazards Models; Pyrimidines - therapeutic use; Rosuvastatin Calcium; Sleep Initiation and Maintenance Disorders - epidemiology; Statins; Stroke; Sulfonamides - therapeutic use; Treatment Outcome; Triglycerides

Recent US guidelines expand the indications for high-intensity statin therapy, yet data on the safety of attaining very low-density lipoprotein cholesterol (LDL-C) levels are scarce. Among 16,304 participants in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating...